InvestorLens

GANX — GAIN THERAPEUTICS INC

Public company

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About GAIN THERAPEUTICS INC (GANX)

GAIN THERAPEUTICS INC (GANX) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by David Einhorn (DME Capital Management, LP), valued at $2M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 2 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in GANX

60
/100
Institutional Accumulation
Added / Increased3
Reduced2
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track GANX

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

GANX Ownership Composition

How GAIN THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Hedge Funds
87% of tracked value
Institutions
4
tracked investors
Total Reported
$1.4M
combined 13F value
Sectors2
  • Hedge Funds86.8%
  • Other13.2%
Hedge Funds(2)
86.8%
Other(2)
13.2%

Tracked investors reporting GANX

  • David EinhornMar 31, 2026
    DME Capital Management, LP
    Shares
    566.1K
    Value
    $1.1M
    % Portfolio
    0.03%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    70.8K
    Value
    $137.4K
    % Portfolio
    0.00%
  • Steve CohenDec 31, 2025
    Point72 Asset Management
    Shares
    32.5K
    Value
    $104.6K
    % Portfolio
    0.00%
  • Izzy EnglanderDec 31, 2025
    Millennium Management
    Shares
    14K
    Value
    $45.1K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold GANX?
4 tracked institutional investors disclosed a position in GANX (GAIN THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of GANX?
David Einhorn, DME Capital Management, LP, holds the largest disclosed position in GANX, valued at $2M.
Did institutional ownership of GANX increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 2 reduced, and 0 fully exited GANX.
Where does this GANX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.